Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 12,232 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Parent Focused Training (PFT), Child Life and Attention Skills (CLAS) Program; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 7 Years to 11 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Berkeley, California • San Francisco, California

Conditions: Fibromyalgia
Interventions: [S,S]-Reboxetine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 101
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 87 more

Conditions: Dyskinesias, Drug-induced
Interventions: AQW051, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Sacramento, California • Manhasset, New York • Cincinnati, Ohio + 1 more

Conditions: Type 2 Diabetes, Obesity
Interventions: EndoBarrier, Sham Procedure; Device · Procedure
Lead sponsor: Morphic Medical Inc.; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 25
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 20 more

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Implant Procedure, Disease-Modifying Therapies (DMTs), Active stimulation, Non-active stimulation; Procedure · Drug · Device
Lead sponsor: SetPoint Medical Corporation; Industry
Eligibility: 22 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 9
States / cities: Irvine, California • Atlanta, Georgia • Baltimore, Maryland + 6 more

Conditions: Non-Small Cell Lung Cancer, Anemia, Cancer, Lung Cancer
Interventions: Darbepoetin alfa, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 2,549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 277
States / cities: Anniston, Alabama • Birmingham, Alabama • Anchorage, Alaska + 243 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: QVA149, QAB149, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 47
States / cities: Vestavia Hills, Alabama • Huntington Beach, California • Lakewood, California + 43 more

Conditions: Non-Small Cell Lung Cancer, Ovarian Cancer, Fallopian Tube Cancer, Triple Negative Breast Cancer, Multiple Myeloma, Pancreatic Ductal Adenocarcinoma
Interventions: CART-TnMUC1, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • Tampa, Florida + 7 more

Conditions: Multiple Myeloma, Neoplasm, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorder, Vascular Diseases, Cardiovascular Diseases, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Lymphoproliferative Disorders, Immunoproliferative Disorders, Immune System Diseases, Antineoplastic Agents, Analgesics, Non-Narcotic, Analgesics, Sensory System Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs
Interventions: CYNK-001; Biological
Lead sponsor: Celularity Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Denver, Colorado • St Louis, Missouri • Buffalo, New York + 1 more

Conditions: Acute Coronary Syndrome
Interventions: VitalScan Magnetocardiograph; Device
Lead sponsor: Creavo Medical Technologies Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 651 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Indianapolis, Indiana • Winston-Salem, North Carolina • Cincinnati, Ohio + 2 more

Conditions: Metastatic Renal Cell Carcinoma
Interventions: Dovitinib, Sorafenib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 34
States / cities: Fayetteville, Arkansas • La Jolla, California • Los Angeles, California + 26 more

Conditions: Multiple Myeloma
Interventions: Bortezomib, Lenalidomide, Dexamethasone, Stem Cell Mobilization, Autologous Stem Cell Transplant; Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 8
States / cities: Denver, Colorado • Brewer, Maine • Boston, Massachusetts + 3 more

Conditions: Asymptomatic Myeloma
Interventions: Atezolizumab (1200mg via IV infusion); Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol; Biological
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 12
States / cities: Palm Desert, California • Pasadena, California • Santa Maria, California + 9 more

Conditions: Multiple Myeloma
Interventions: Belumosudil mesylate; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Atypical Hemolytic Uremic Syndrome
Interventions: Not listed
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 16
States / cities: Atlanta, Georgia • Dunwoody, Georgia • Fort Wayne, Indiana + 12 more

Conditions: Relapsing Multiple Sclerosis, Multiple Sclerosis
Interventions: Placebo, Pirtobrutinib; Drug
Lead sponsor: Loxo Oncology, Inc.; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Tampa, Florida • Houston, Texas • Seattle, Washington

Conditions: Breast Cancer
Interventions: None (Observational Study); Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 40
States / cities: Mobile, Alabama • Chandler, Arizona • Little Rock, Arkansas + 36 more

Conditions: Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer, Gastric Cancer, Melanoma, Renal Cell Carcinoma, Pancreatic Cancer, Cervical Cancer, Triple Negative Breast Cancer, Advanced Cancer, Metastatic Cancer
Interventions: Alomfilimab, Atezolizumab; Drug
Lead sponsor: Kymab Limited; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 6
States / cities: Duarte, California • New Haven, Connecticut • Orlando, Florida + 3 more

Conditions: Type 2 Diabetes Mellitus
Interventions: ORMD-0801 (qd), ORMD-0801 (bid), ORMD-0801 (tid), Placebo; Drug · Other
Lead sponsor: Oramed, Ltd.; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tustin, California

Conditions: Humerus Fracture Metastatic Bone Disease
Interventions: Photodynamic Bone Stabilization System; Device
Lead sponsor: IlluminOss Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 13
States / cities: Redwood City, California • Washington D.C., District of Columbia • Atlanta, Georgia + 10 more

Conditions: Myeloma, Stem Cell Transplantation
Interventions: Lenalidomide, Melphalan, Stem Cell Infusion; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Trastuzumab, Pertuzumab, Tocilizumab; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Chicago, Illinois • Ann Arbor, Michigan • New Haven, New York

Conditions: Hypertriglyceridemia
Interventions: CaPre, Placebo; Drug
Lead sponsor: Grace Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 53
States / cities: Birmingham, Alabama • Childersburg, Alabama • Encino, California + 44 more

Search by objective public record fields.

Effectiveness of a Behavioral Treatment Program for Attention Deficit Hyperactivity Disorder, Inattentive Type

Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia

Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese

The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

VitalScan MCG Rule-out Multi-centre Pivotal Study - US

Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma

aHUS Observational Long Term Follow-Up

A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis

An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus

Safety and Efficacy Study of Treatment of Pathological Fractures in Humerus

Lenalidomide and High-Dose Melphalan

Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab

A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)